[Federal Register Volume 75, Number 243 (Monday, December 20, 2010)]
[Rules and Regulations]
[Pages 79296-79300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-31854]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-331F]
Schedules of Controlled Substances: Placement of 5-Methoxy-N,N-
Dimethyltryptamine into Schedule I of the Controlled Substances Act
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: With the issuance of this final rule, the Deputy Administrator
of the Drug Enforcement Administration (DEA) places the substance 5-
methoxy-N,N-dimethyltryptamine (5-MeO-DMT), including its salts,
isomers and salts of isomers whenever the existence of such salts,
isomers, and salts of isomers is possible, into schedule I of the
Controlled Substances Act (CSA). This action by the DEA Deputy
Administrator is based on a scheduling recommendation from the
Assistant Secretary for Health of the Department of Health and Human
Services (DHHS) and a DEA review indicating that 5-MeO-DMT meets the
criteria for placement in schedule I of the CSA. This final rule will
impose the criminal sanctions and regulatory controls of schedule I
substances under the CSA on the manufacture, distribution, dispensing,
importation, exportation, and possession of 5-MeO-DMT.
DATES: Effective Date: January 19, 2011.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, PhD, Chief,
Drug and Chemical Evaluation Section, Office of Diversion Control, Drug
Enforcement Administration, 8701 Morrissette Drive, Springfield,
Virginia 22152, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION:
Background
In accordance with 21 U.S.C. 811(b) of the CSA, DEA gathered and
reviewed the available information regarding the pharmacology,
chemistry, trafficking, actual abuse, pattern of abuse, and the
relative potential for abuse of 5-methoxy-N,N-dimethyltryptamine (5-
MeO-DMT). On February 21, 2007, the Deputy Administrator of the DEA
submitted these data to the Assistant Secretary for Health, Department
of Health and Human Services. In accordance with 21 U.S.C. 811(b), the
Deputy Administrator also requested a scientific and medical evaluation
and a scheduling recommendation for 5-MeO-
[[Page 79297]]
DMT from the Assistant Secretary for Health.
5-MeO-DMT is related to the schedule I hallucinogens N,N-
dimethyltryptamine (DMT), 2,5-dimethoxy-4-methylamphetamine (DOM),
lysergic acid diethylamide (LSD) and mescaline in its pharmacological
properties and hallucinogenic effects. In animal drug discrimination
studies, DOM, LSD, mescaline, DMT, and alpha-methyltryptamine (AMT)
fully substitute for the discriminative stimulus cue of 5-MeO-DMT. In
in vitro receptor binding studies, 5-MeO-DMT, similar to DMT and other
schedule I hallucinogens, binds to central serotonin 2 (5-
HT2) receptors. Anecdotal reports from humans who have used
5-MeO-DMT describe hallucinogenic effects similar to those produced by
DMT. 5-MeO-DMT, however, is reported to be 4 to 5-fold more potent than
DMT when administered by inhalation, sublingual or oral (if
encapsulated) routes of administration.
Evidence of 5-MeO-DMT trafficking was first reported in 1999 by
Federal law enforcement officials. Though 5-MeO-DMT is likely to be
underreported because it is not a controlled substance, from January
1999 to December 2009, law enforcement officials encountered 23 cases
involving 35 drug exhibits pertaining to the trafficking, distribution
and abuse of 5-MeO-DMT, according to the System to Retrieve Information
from Drug Evidence (STRIDE), a Federal database of drug exhibits
analyzed by DEA laboratories. The drug exhibits analyzed by DEA
laboratories comprised 89 grams of powder and 10 milliliters of liquid
containing 5-MeO-DMT. From January 2004 to December 2009, the National
Forensic Laboratory Information System (NFLIS), a database of drug
analyses conducted by State and local forensic laboratories, reported
27 State and local drug cases involving 32 drug exhibits identified as
5-MeO-DMT.
The risks to the public health associated with the abuse of 5-MeO-
DMT are similar to the risks associated with those of schedule I
hallucinogens. There have been reports of emergency room admissions and
a death associated with the abuse of 5-MeO-DMT. 5-MeO-DMT has never
been approved by the Food and Drug Administration (FDA) for marketing
as a human drug product in the United States and there are no
recognized therapeutic uses of 5-MeO-DMT in the United States.
Notice of Proposed Rulemaking
On December 18, 2008, the Principal Deputy Assistant Secretary for
Health, Department of Health and Human Services (DHHS), sent the Deputy
Administrator of the DEA a scientific and medical evaluation and a
letter recommending that 5-MeO-DMT and its salts be placed into
schedule I of the CSA. Enclosed with the letter was a document prepared
by FDA entitled, ``Basis for the Recommendation To Control 5-Methoxy-
Dimethyltryptamine (5-MeO-DMT) in Schedule I of the Controlled
Substances Act.'' The document contained a review of the factors which
the CSA requires the Secretary to consider (21 U.S.C. 811(b)).
After a review of the available data, including the scientific and
medical evaluation and the scheduling recommendation from DHHS, the
Deputy Administrator of the DEA published a Notice of Proposed
Rulemaking entitled ``Schedules of Controlled Substances: Placement of
5-Methoxy-Dimethyltryptamine into Schedule I of the Controlled
Substances Act'' on August 21, 2009 (74 FR 42217), which proposed
placement of 5-MeO-DMT in schedule I of the CSA. The proposed rule
provided an opportunity for all interested persons to submit their
written comments on or before September 21, 2009.
After the comment period closed on September 21, 2009, DEA
discovered that the supporting documents referenced in the proposed
rule were not posted to the electronic docket, thus not available for
review. DEA reopened the public comment period (October 28, 2009,
Notice of Proposed Rulemaking) (74FR55502) for an additional 30 days to
ensure all interested members of the public had an opportunity to
review all the materials and provide comments. Comments submitted on or
before November 27, 2009, were considered.
Comments Received
The DEA received 22 comments in response to the August 21, 2009,
and October 28, 2009, Notices of Proposed Rulemaking. Five comments
were received in response to the first Notice of Proposed Rulemaking.
An additional 17 comments were received during the 30-day reopening of
the comment period. One of the comments submitted contained only
supporting materials for another comment that was submitted. All
commenters were concerned citizens, none of whom identified themselves
as representing organizations.
Support for the rule as proposed: One commenter supported the
proposal to schedule 5-MeO-DMT in schedule I. DEA appreciates the
support of this commenter for this final rule.
Twenty of the comments were in opposition to the proposed
scheduling of 5-MeO-DMT in schedule I of the CSA. Various reasons for
the disapproval of the scheduling of 5-MeO-DMT were provided. Most
comments can be grouped into the following general categories: (1)
Those concerned that the comment or request for hearing period was
inadequate and requesting an extension of the comment or request for
hearing period, (2) those concerned that 5-MeO-DMT is a naturally
occurring substance and thus should not be controlled, (3) those that
questioned the pharmacological and abuse potential findings considered
by DEA and DHHS for the purpose of scheduling 5-MeO-DMT, (4) those
concerned that the proposed scheduling would limit access to 5-MeO-DMT
for research, and (5) those that alleged violations of the
Establishment Clause and/or the Free Exercise Clause of the First
Amendment or raised other legal challenges.
Length of comment or request for hearing period: Several commenters
felt that the length of the comment or request for hearing period was
too short and requested that the comment or request for hearing period
be extended, to as much as 24 months. Some commenters noted the need to
research pharmacological, religious or other evidence regarding 5-MeO-
DMT and prepare comments and stated there was not enough time before
the comment period closed to obtain or prepare this information.
In response to these comments, DEA does not believe that a further
extension or reopening of the comment or request for hearing period is
necessary or warranted. Pharmacological and abuse data on 5-MeO-DMT are
publicly available and easily retrievable. The period for comments and
requests for hearings with regard to the Notices of Proposed Rulemaking
was thirty (30) days from the date of publication of each Notice of
Proposed Rulemaking. Interested persons who wished to submit written
data, views or arguments have had ample opportunity to use the
information in the medical and scientific literature, which are
available to the public from various resources (e.g., U.S. National
Library of Medicine, public libraries, and Web sites of scientific
journals), along with the supplemental information provided by DEA
(i.e., DEA's scheduling review document and FDA's scientific and
medical evaluation and scheduling recommendation) as well as other
sources of information such as publications by Federal agencies (e.g.,
reports from DEA's NFLIS, National Institute on Drug Abuse's (NIDA)
National Survey on Drug Use and Health, Substance Abuse and Mental
[[Page 79298]]
Health Services Administration's Drug Abuse Warning Network, and NIDA's
Monitoring the Future) to submit meaningful comments on 5-MeO-DMT that
can be supported by data or scientific arguments. These data are
publicly available and easily retrievable. DEA has considered the
amount of time needed to obtain and review documents and supporting
materials relevant to the commenter's position, prepare the comment,
and submit the comment and finds that a 30-day comment period provides
a meaningful opportunity for interested persons to submit comments or
request a hearing. While commenters indicated that an extension of the
comment period would allow time for further research regarding 5-MeO-
DMT, DEA notes that this scheduling action does not prevent such
research from occurring. Any person wishing to conduct research using
5-MeO-DMT may do so provided that the person has obtained a schedule I
researcher registration with DEA, has the appropriate research
protocols in place with FDA, and meets all other requirements.
Use of http://www.regulations.gov: Several commenters discussed the
use of http://www.regulations.gov, the government's online Federal
Docket Management System (FDMS). Commenters stated that the document
reopening the comment period was posted to the electronic docket on
http://www.regulations.gov on October 28, 2009, but that certain
supporting materials were not posted until November 3, 2009. In a
related comment, a commenter objected to the ``splitting'' of the
electronic docket for the reopening of the comment period from the
electronic docket for the Notice of Proposed Rulemaking. The commenter
indicated that ``splitting'' the dockets made it difficult to view all
docket components and made it ``extremely difficult to communicate to
others where and how to locate, view, or comment on Docket No. DEA-
331.''
DEA disagrees with these comments. The supporting documents were
posted to the electronic docket (Docket ID DEA 2009-0008) on September
30, 2009, and October 2, 2009. DEA acknowledges that the electronic
docket for the Notice of Proposed Rulemaking was separate from the
electronic docket for the reopening of the comment period. This
electronic method of posting, however, merely supplemented the notice
provisions required by the Administrative Procedure Act (5 U.S.C. 553).
Both the Notice of Proposed Rulemaking and the extension of the comment
period were published in the Federal Register (74 FR 42217, August 21,
2009, and 74 FR 55502, October 28, 2009, respectively), in accordance
with administrative law requirements. Although not required to do so,
DEA posted a Statement for the Record in the Federal Docket Management
System (FDMS) Docket ID DEA-2009-0008 (the August 21, 2009, Notice of
Proposed Rulemaking) to alert the public that the Notice of Proposed
Rulemaking to reopen the comment period was located in FDMS Docket ID
DEA-2009-0013.
5-MeO-DMT is a naturally occurring substance: Some commenters
objected to the proposed scheduling of 5-MeO-DMT because 5-MeO-DMT is a
naturally occurring substance. DEA has considered these comments and
acknowledges the biological presence of 5-MeO-DMT in humans and in
certain toads and plant species. However, DEA disagrees with the
contention that the fact that 5-MeO-DMT is a naturally occurring
substance prevents it from being controlled. DHHS and DEA have
considered the eight factors determinative of control set out in 21
U.S.C. 811(c), and DEA has considered the recommendations of DHHS in
making the findings under 21 U.S.C. 812 that warrant placement in
schedule I of the CSA.
Insufficient data: Several commenters believed that insufficient
data exist to support the placement of 5-MeO-DMT into schedule I. For
example, a few commenters argued that 5-MeO-DMT does not have toxic
effects or lead to addiction or harmful behavior. In addition, a
commenter incorrectly stated that there were no reported deaths
associated with the use of 5-MeO-DMT. Other commenters suggested that
the scheduling of 5-MeO-DMT be postponed until more research could be
done.
DEA does not agree with these statements. The studies used to
assess abuse potential of 5-MeO-DMT are widely held as the standard
methods of evaluation. Behavioral effects of 5-MeO-DMT in animals and
humans were found to be similar to those of the schedule I
hallucinogens. Preclinical studies indicated that 5-MeO-DMT has
pharmacological effects at serotonin receptors. In humans, 5-MeO-DMT
produced subjective responses similar to DMT and other schedule I
hallucinogens. In addition, DEA finds that the abuse of 5-MeO-DMT
presents a safety hazard to the health of individuals. There are
reports of emergency room admissions and a death associated with the
abuse of 5-MeO-DMT. After careful consideration of preclinical and
clinical studies and in accordance with 21 U.S.C. 811(a) and (b) and
considering the factors enumerated in 21 U.S.C. 811(c), the Deputy
Administrator of the DEA finds that 5-MeO-DMT has high abuse potential
supporting placement in schedule I under the CSA.
Control of DMT: One commenter questioned the evidence considered by
DEA to make the findings to control ``DMT.'' DEA finds that this
comment is not relevant to the present scheduling action as this Final
Rule pertains to the scheduling of 5-MeO-DMT. However, if the commenter
intended to refer to 5-MeO-DMT and not DMT, the reasons for controlling
5-MeO-DMT have already been provided.
Prohibition or restriction of use in research: Commenters expressed
concern that the proposed scheduling of 5-MeO-DMT will prohibit or
significantly restrict the use of 5-MeO-DMT in research. The DEA does
not agree. As noted previously, persons interested in using 5-MeO-DMT
for research purposes can still use this substance provided that they
have a DEA schedule I researcher registration and meet all other
statutory and regulatory criteria. This registration can be obtained by
submitting an application for schedule I registration in accordance
with 21 CFR 1301.18.
Constitutional concerns: Several commenters raised concerns that
the proposed rule would substantially impair religious liberty. The
commenters raised two specific concerns with respect to religion.
First, the commenters questioned the proposed rule on the ground that
the CSA, which authorizes this rulemaking, violates both the Free
Exercise Clause and the Establishment Clause of the First Amendment.
DEA has fully considered these concerns, and does not believe any
change in the rule is necessary. With respect to the Free Exercise
Clause, one commenter claimed that the CSA is not a neutral law of
general applicability under Employment Division v. Smith, 494 U.S. 872
(1990), because the CSA includes exemptions for the use of alcohol,
certain research and medical uses of certain substances, and the
sacramental use of peyote by the Native American Church. This concern
has been raised previously in litigation, and courts have concluded
that the CSA does not interfere with the free exercise of religion in
violation of the First Amendment. See Olsen v. Mukasey, 541 F.3d 827
(8th Cir. 2008); O Centro Espirita Beneficiente Uniao do Vegetal v.
Mukasey, No. 00-1647 (D. N. M. June 16, 2008). The commenter raised
similar concerns about the CSA with respect to the Establishment Clause
of the First Amendment. Once again, courts have
[[Page 79299]]
upheld the validity of the CSA in the face of related challenges and
concluded that the statute does not represent an establishment of
religion in contravention of the First Amendment. Peyote Way Church of
God v. Thornburgh, 922 F.2d 1210 (5th Cir. 1991); United States v.
Valazquez, 2009 WL 2823730 (W.D. Okla. Aug. 31, 2009).
Another commenter suggested that if the final rule scheduling 5-
MeO-DMT is issued without change, DEA should consider ``providing
special exemption for religious use.'' The commenter did not provide
any specific details about the kind of exemption that he believed would
be appropriate. Accordingly, DEA lacks the information necessary to
evaluate this comment.
Finally, one commenter questioned DEA's finding that the proposed
rule does not have federalism implications warranting the application
of Executive Order 13132. DEA has considered this concern and concurs
with the conclusion that the placement of 5-MeO-DMT and its salts into
schedule I of the CSA does not preempt or modify any provision of State
law; nor does it impose enforcement responsibilities on any State; nor
does it diminish the power of any State to enforce its own laws.
Scheduling of 5-MeO-DMT
Based on the recommendation of the Assistant Secretary for Health,
received in accordance with section 201(b) of the Act (21 U.S.C.
811(b)), the independent review of the available data by DEA, and after
a review of the comments received in response to the Notice of Proposed
Rulemaking and the notice reopening the comment period, the Deputy
Administrator, pursuant to sections 201(a) and 201(b) of the Act (21
U.S.C. 811(a) and 811(b)), finds that:
(1) 5-MeO-DMT has a high potential for abuse.
(2) 5-MeO-DMT has no currently accepted medical use in treatment in
the United States.
(3) There is a lack of accepted safety for use of 5-MeO-DMT under
medical supervision.
Based on these findings, the Deputy Administrator of the DEA
concludes that 5-MeO-DMT and its salts warrant control in schedule I of
the CSA (21 U.S.C. 812 (b)(1)).
Regulatory Requirements
As noted below, 5-MeO-DMT will be subject to regulatory controls
and administrative, civil and criminal sanctions applicable to the
manufacture, distribution, dispensing, importation and exportation of a
schedule I controlled substance, including the following:
Registration. Any person who manufactures, distributes, dispenses,
imports or exports 5-MeO-DMT or who engages in research or conducts
instructional activities with respect to 5-MeO-DMT, or who proposes to
engage in such activities, must submit an application for schedule I
registration in accordance with part 1301 of Title 21 of the Code of
Federal Regulations. Any person who is currently engaged in any of the
above activities and is not registered with DEA must submit an
application for registration on or before January 19, 2011 and may
continue their activities until DEA has approved or denied that
application.
Security. 5-MeO-DMT is subject to schedule I security requirements
and must be manufactured, distributed and stored in accordance with
Sec. Sec. 1301.71; 1301.72(a), (c), and (d); 1301.73; 1301.74;
1301.75(a) and (c); and 1301.76 of Title 21 of the Code of Federal
Regulations on or after January 19, 2011.
Labeling and Packaging. All labels and labeling for commercial
containers of 5-MeO-DMT which are distributed on or after January 19,
2011 must comply with the requirements of Sec. Sec. 1302.03 through
1302.07 of Title 21 of the Code of Federal Regulations on or after
January 19, 2011.
Quotas. Quotas for 5-MeO-DMT must be established pursuant to the
requirements of part 1303 of Title 21 of the Code of Federal
Regulations.
Inventory. Every registrant required to keep records and who
possesses any quantity of 5-MeO-DMT must keep an inventory of all
stocks of 5-MeO-DMT on hand pursuant to Sec. Sec. 1304.03, 1304.04 and
1304.11 of Title 21 of the Code of Federal Regulations on or after
January 19, 2011. Every registrant who desires registration in schedule
I to handle 5-MeO-DMT must conduct an inventory of all stocks of the
substance.
Records. All registrants who handle 5-MeO-DMT must keep records
pursuant to Sec. Sec. 1304.03, 1304.04, 1304.21, 1304.22, and 1304.23
of Title 21 of the Code of Federal Regulations on or after January 19,
2011.
Reports. All registrants required to submit reports in accordance
with Sec. 1304.33 of Title 21 of the Code of Federal Regulations must
do so regarding 5-MeO-DMT on and after January 19, 2011.
Order Forms. All registrants involved in the distribution of 5-MeO-
DMT must comply with the order form requirements of part 1305 of Title
21 of the Code of Federal Regulations on and after January 19, 2011.
Importation and Exportation. All importation and exportation of 5-
MeO-DMT must be in compliance with part 1312 of Title 21 of the Code of
Federal Regulations on or after January 19, 2011.
Criminal Liability. Any activity with 5-MeO-DMT not authorized by,
or in violation of, the Controlled Substances Act or the Controlled
Substances Import and Export Act shall be unlawful on or after January
19, 2011.
Regulatory Certifications
Executive Order 12866
In accordance with the provisions of the CSA (21 U.S.C. 811(a)),
this action is a formal rulemaking ``on the record after opportunity
for a hearing.'' Such proceedings are conducted pursuant to the
provisions of 5 U.S.C. 556 and 557 and, as such, are exempt from review
by the Office of Management and Budget pursuant to Executive Order
12866, section 3(d)(1).
Regulatory Flexibility Act
The Deputy Administrator, in accordance with the Regulatory
Flexibility Act (5 U.S.C. 601-612), has reviewed this final rule and by
approving it certifies that it will not have a significant economic
impact on a substantial number of small entities. This action involves
the control of a substance with no currently accepted medical use in
treatment in the United States. This final rule will place 5-MeO-DMT
into schedule I of the Controlled Substances Act.
Executive Order 12988
This regulation meets the applicable standards set forth in
Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice
Reform.
Executive Order 13132
This rulemaking does not preempt or modify any provision of State
law; nor does it impose enforcement responsibilities on any State; nor
does it diminish the power of any State to enforce its own laws.
Accordingly, this rulemaking does not have federalism implications
warranting the application of Executive Order 13132.
Unfunded Mandates Reform Act of 1995
This rule will not result in the expenditure by State, local and
Tribal governments, in the aggregate, or by the private sector, of
$126,400,000 or more (adjusted for inflation) in any one year, and will
not significantly or uniquely affect small governments. Therefore, no
actions were deemed necessary under provisions of the Unfunded Mandates
Reform Act of 1995.
[[Page 79300]]
Congressional Review Act
This rule is not a major rule as defined by Sec. 804 of the Small
Business Regulatory Enforcement Fairness Act of 1996 (Congressional
Review Act). This rule will not result in an annual effect on the
economy of $100,000,000 or more; a major increase in costs or prices:
or significant adverse effects on competition, employment, investment,
productivity, innovation, or on the ability of United States-based
companies to compete with foreign based companies in domestic and
export markets.
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Narcotics, Prescription drugs.
Under the authority vested in the Attorney General by section
201(a) of the CSA (21 U.S.C. 811(a)), and delegated to the
Administrator of DEA by Department of Justice regulations (28 CFR
0.100), and redelegated to the Deputy Administrator pursuant to 28 CFR
0.104, the Deputy Administrator hereby amends 21 CFR part 1308 as
follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b) unless otherwise noted.
0
2. Section 1308.11 is amended by:
0
A. Redesignating existing paragraphs (d)(15) through (d)(34) as
paragraphs (d)(16) through (d)(35); and
0
B. Adding a new paragraph (d)(15).
Sec. 1308.11 Schedule I.
* * * * *
(d) * * *
(15) 5-methoxy-N,N-dimethyltryptamine 7431. Some trade or other
names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT
* * * * *
Dated: December 13, 2010.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 2010-31854 Filed 12-17-10; 8:45 am]
BILLING CODE 4410-09-P